Trial Profile
A phase I study of CD19-TAC01 in patients with diffuse large B cell lymphoma (DLBCL)
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 20 Sep 2018
Price :
$35
*
At a glance
- Drugs CD19-TAC01 (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions
- 20 Sep 2018 New trial record
- 10 Sep 2018 According to a Centre for the Commercialization of Antibodies and Biologics media release, Triumvira anticipates to initiate this study in first half of 2019.